{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:01:30Z","timestamp":1790096490407,"version":"4.0.1"},"reference-count":45,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: Carbapenem-resistant Enterobacterales (CRE) infections represent a critical global health threat with limited therapeutic options and high mortality rates. Novel \u03b2-lactam\/\u03b2-lactamase inhibitor (BL\/BLI) combinations have emerged, but their comparative impact on survival versus best available therapy (BAT) remains to be comprehensively assessed. This systematic review evaluates the mechanistic, microbiological, and genetic factors affecting treatment success. Methods: Randomized controlled trials (RCTs) and observational reports published up to December 2025 were included. An intensive search strategy was conducted through PubMed\/Medline, Embase, Scopus, Cochrane, and Web of Science databases. The trials compared novel BL\/BLI agents ceftazidime\/avibactam (CAZ-AVI), Meropenem\/Vaborbactam (MER-VABO), and Imipenem\/Cilastatin\/Relebactam (IPM-CIL-REL) to BAT for CRE infections that reported all-cause mortality in adult hospitalized patients (\u226518 years). Data retrieval included carbapenemase types, resistance mechanisms, and minimum inhibitory concentrations (MICs). Risk ratios (RRs), heterogeneity (I2), and publication bias were measured using appropriate statistical models. Results: The meta-analysis included nine primary studies (six RCTs and three observational cohorts) with 2892 CRE-infected patients. Compared to BAT, BL\/BLI combinations significantly reduced mortality by 27% (pooled RR = 0.73; 95% Confidence Intervals (CI): 0.59\u20130.9; p = 0.003), with low heterogeneity (I2 = 38%). Treatment outcomes differed substantially by carbapenemase type. For Klebsiella pneumoniae carbapenemase (KPC)-producing strains, meropenem\u2013vaborbactam was most effective (RR = 0.65; 95% CI: 0.49\u20130.94), while ceftazidime\u2013avibactam was superior for OXA-48-like producers (RR = 0.55; 95% CI: 0.41\u20130.82). No BL\/BLI combination demonstrated efficacy against metallo-\u03b2-lactamase (MBL)-producing strains. Among hospitalized high-risk patients (e.g., septic shock), meropenem\u2013vaborbactam (RR = 0.65) and colistin-based therapy (RR = 0.61) were most effective for mortality reduction. Meta-regression proved that the proportion of KPC-producing isolates significantly predicted effect size (coefficient: \u22120.42, 95% CI: \u22120.68 to \u22120.16, p = 0.002). Funnel plot asymmetry indicated possible publication bias (Egger\u2019s test p = 0.09). Conclusions: Innovative BL\/BLI combinations lower all-cause mortality compared to BAT. This effect is extremely reliant on the comparator regimen composition, the specific BL\/BLI drug, and the underlying resistance mechanism. These data support a precision medicine approach guided by rapid molecular diagnostics. These findings underscore the urgent need for novel agents against MBL-producing strains, including the recently approved aztreonam\u2013avibactam.<\/jats:p>","DOI":"10.3390\/antibiotics15090928","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:28:43Z","timestamp":1790090923000},"page":"928","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel \u03b2-Lactam\/\u03b2-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3522-0607","authenticated-orcid":false,"given":"Basim Raddam","family":"Al Shammari","sequence":"first","affiliation":[{"name":"Department of Medical Surgical and Critical Care Nursing, College of Nursing, University of Hafr Al Batin, Hafr Albatin 39831, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Salam, M.A., Al-Amin, M.Y., Salam, M.T., Pawar, J.S., Akhter, N., Rabaan, A.A., and Alqumber, M.A.A. (2023). Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare, 11.","DOI":"10.20944\/preprints202305.0555.v1"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jgar.2022.06.019","article-title":"Clinical epidemiology of carbapenem-resistant Enterobacterales in the Greater Houston region of Texas: A 6-year trend and surveillance analysis","volume":"30","author":"Tadese","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.33393\/dti.2023.2622","article-title":"Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection","volume":"17","author":"Osaithai","year":"2023","journal-title":"Drug Target Insights"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"ofv050","DOI":"10.1093\/ofid\/ofv050","article-title":"Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections","volume":"2","author":"Morrill","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3947\/ic.2024.0038","article-title":"Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections","volume":"56","author":"Park","year":"2024","journal-title":"Infect. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101996","DOI":"10.1016\/j.cegh.2025.101996","article-title":"Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients","volume":"33","author":"Gumudavelli","year":"2025","journal-title":"Clin. Epidemiol. Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/14656566.2019.1660772","article-title":"The latest advances in \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections","volume":"20","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients with Imipenem-nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"dlac106","DOI":"10.1093\/jacamr\/dlac106","article-title":"Comparative effectiveness of antibiotic therapy for carbapenem-resistant Enterobacterales (CRE) bloodstream infections in hospitalized US veterans","volume":"4","author":"Wilson","year":"2022","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e00047-19","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of \u03b2-Lactamase-Producing Pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00064-16","article-title":"Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes","volume":"30","author":"Poirel","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Coppola, N., Maraolo, A.E., Onorato, L., Scotto, R., Cal\u00f2, F., De Pascalis, S., Borrelli, M., and Gentile, I. (2022). Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion. Antibiotics, 11.","DOI":"10.3390\/antibiotics11091263"},{"key":"ref_16","first-page":"e01730-17","article-title":"A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae","volume":"62","author":"Vos","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yu, W., Shen, P., Luo, Q., Xiong, L., and Xiao, Y. (2022). Efficacy and safety of novel carbapenem-\u03b2-lactamase inhibitor combinations: Results from phase II and III trials. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.925662"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.2147\/IDR.S390635","article-title":"Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review","volume":"15","author":"Hu","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10096-023-04577-x","article-title":"Rapid diagnostics and ceftazidime\/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: Impact on mortality and role of combination therapy","volume":"42","author":"Boattini","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10096-023-04712-8","article-title":"Prevalence and mortality of ceftazidime\/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018\u20132022)","volume":"43","author":"Boattini","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem\/Cilastatin\/Relebactam Versus Piperacillin\/Tazobactam in Adults with Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of Meropenem-Vaborbactam vs. Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e02313-19","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Arboleda, D., Buitrago, C., Vergara, E.P., Nocua-B\u00e1ez, L.C., Saavedra, C.H., Garc\u00eda, J.S., Gualtero, S., Rinc\u00f3n, M.J., Buitrago, C.A., and Porras, J.A. (2025). Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Antibiotics, 14.","DOI":"10.3390\/antibiotics14030226"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/8755122520934726","article-title":"Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem\/Cilastatin-Relebactam to Target Klebsiella pneumoniae Carbapenemase-Producing Enterobacterales","volume":"36","author":"Hayden","year":"2020","journal-title":"J. Pharm. Technol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e12047","DOI":"10.1002\/cesm.12047","article-title":"Standardized mean differences in meta-analysis: A tutorial","volume":"2","author":"Richardson","year":"2024","journal-title":"Cochrane Evid. Synth. Methods"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00487-19","DOI":"10.1128\/AAC.00487-19","article-title":"Structural Insights into the Inhibition of the Extended-Spectrum \u03b2-Lactamase PER-2 by Avibactam","volume":"63","author":"Ruggiero","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Abu Jaber, A.M.R., Basgut, B., Hawan, A.A., Al Shehri, A.A., AlKahtani, S.A., Alharbi, F.S., AlSaif, A.M., Alsuhibani, S.A., Alqahtani, M.S., and Alghamdi, M.A. (2024). The Clinical Efficacy of Adding Ceftazidime\/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae with blaOXA-48-like Genes. Antibiotics, 13.","DOI":"10.3390\/antibiotics13030265"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kumar, V., Viviani, S.L., Ismail, J., Agarwal, S., Bonomo, R.A., and van den Akker, F. (2021). Structural analysis of the boronic acid \u03b2-lactamase inhibitor vaborbactam binding to Pseudomonas aeruginosa penicillin-binding protein 3. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0258359"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa","volume":"76","author":"Isler","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","first-page":"411","article-title":"Ceftazidime-avibactam: A retrospective analysis of multicenter real-world data and factors affecting mortality","volume":"4","author":"Ural","year":"2025","journal-title":"Infect. Dis. Clin. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"dlaf096","DOI":"10.1093\/jacamr\/dlaf096","article-title":"Clinical efficacy, safety and pharmacokinetics of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: A systematic review","volume":"7","author":"Isla","year":"2025","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Karaiskos, I., Galani, I., Daikos, G.L., and Giamarellou, H. (2025). Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs. Antibiotics, 14.","DOI":"10.3390\/antibiotics14050528"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kong, H., Liu, Y., Wang, Y., Yang, L., Chen, Q., Wang, J., Liu, Y., Zhang, Y., Li, Z., and Zhang, X. (2026). Risk factors, and outcomes of patients with carbapenem-resistant Enterobacterales bloodstream infection: An eight-year case-case-control study. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1734801"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3343\/alm.2020.40.3.259","article-title":"Rapid Identification of OXA-48-like, KPC, NDM, and VIM Carbapenemase-Producing Enterobacteriaceae From Culture: Evaluation of the RESIST-4 O.K.N.V. Multiplex Lateral Flow Assay","volume":"40","author":"Song","year":"2020","journal-title":"Ann. Lab. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"dlaf238","DOI":"10.1093\/jacamr\/dlaf238","article-title":"The impact of ceftazidime-avibactam on 30-day mortality in the treatment of OXA-48 producing Enterobacterales infections: A systematic review and meta-analysis","volume":"8","author":"Foo","year":"2026","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.53841\/bpsicpr.2020.15.2.123","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","volume":"15","author":"Higgins","year":"2020","journal-title":"Int. Coach. Psychol. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e076912","DOI":"10.1136\/bmjopen-2023-076912","article-title":"Inter-reviewer reliability of human literature reviewing and implications for the introduction of machine-assisted systematic reviews: A mixed-methods review","volume":"14","author":"Hanegraaf","year":"2024","journal-title":"BMJ Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Vierra, A., Razzaq, A., and Andreadis, A. (2023). Categorical variable analyses. Translational Surgery, Academic Press.","DOI":"10.1016\/B978-0-323-90300-4.00095-1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/9\/928\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:01:26Z","timestamp":1790092886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/9\/928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["antibiotics15090928"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15090928","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}